Best-in-Class potential with improved therapeutic index compared to other armed antibodies Synthon Biopharmaceuticals, a subsidiary of specialty pharma company Synthon, has reported promising results with its lead program of antibody-drug conjugates (ADCs). In pre-clinical xenograft studies...
Revotar Biopharmaceuticals AG / Revotar Biopharmaceuticals AG Starts Phase II Clinical Trial in COPD Patients with inhaled Bimosiamose processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. Revotar Biopharmaceuticals AG today announced the...
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) (the "Company") announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data...
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) (the "Company") announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data...
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) (the "Company") announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data...
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) (the "Company") announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data...
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) (the "Company") announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data...